European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading

MT Newswires Live05-29

European equities traded in the US as American depositary receipts were moving sharply lower Wednesday morning, falling 1.39% to 1,402.95 on the S&P Europe Select ADR Index.

Gainers in continental Europe were led by biopharmaceutical companies Genfit (GNFT) and DBV Technologies (DBVT), which climbed 11% and 7.8% respectively. They were followed biopharmaceutical company by argenx (ARGX) and internet advertising firm Criteo (CRTO), which increased 4.5% and 1.8% respectively.

The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company Grifols (GRFS), which fell 7.5% and 5.1% respectively. They were followed by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which dropped 4.6% and 3.4% respectively.

In the UK and Ireland, the only gainers were biotech firm Trinity Biotech (TRIB) and pharmaceutical company GSK (GSK), which rose 1.2% and 0.01% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Biodexa Pharmaceuticals (BDRX), which lost 5% and 4.6% respectively. They were followed by cruise line operator Carnival (CUK) and gas and electricity provider National Grid (NGG), which were down 4% and 3.9% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment